Intracrine angiotensin ii functions originate from noncanonical pathways in the human heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 311, Issue 2, 2016, Pages H404-H414

  Ferrario, Carlos M ^a   Ahmad, Sarfaraz ^a   Varagic, Jasmina ^a   Cheng, Che Ping ^a   Groban, Leanne ^a   Wang, Hao ^a   Collawn, James F ^b   Dell’Italia, Louis J ^b,c  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin (1 12); Heart chymase; Heart failure; Hypertension

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; ANGIOTENSIN-(1-12), HUMAN; CHYMASE; PEPTIDE FRAGMENT;

ARTICLE; HEART; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CARDIAC MUSCLE; HEART VENTRICLE REMODELING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR REMODELING;

ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; CHYMASES; HEART; HUMANS; MYOCARDIUM; PEPTIDE FRAGMENTS; RENIN-ANGIOTENSIN SYSTEM; VASCULAR REMODELING; VENTRICULAR REMODELING;

EID: 84983650232     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00219.2016     Document Type: Article

References (160)

1. Abadir PM, Walston JD, Carey RM. Subcellular characteristics of functional intracellular renin-angiotensin systems. Peptides 38: 437-445, 2012.
2. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin- (1-12) in human atrial tissue. PLoS One 6: e28501, 2011.
3. Ahmad S, Varagic J, Groban L, Dell’Italia LJ, Nagata S, Kon ND, Ferrario CM. Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep 16: 429, 2014.
4. Ahmad S, Varagic J, Westwood BM, Chappell MC, Ferrario CM. Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One 6: e15759, 2011.
5. Ahmad S, Wei CC, Tallaj J, Dell’Italia LJ, Moniwa N, Varagic J, Ferrario CM. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens 7: 128-136, 2013.
6. Arakawa H, Chitravanshi VC, Sapru HN. The hypothalamic arcuate nucleus: a new site of cardiovascular action of angiotensin-(1-12) and angiotensin II. Am J Physiol Heart Circ Physiol 300: H951-H960, 2011.
7. Arakawa H, Kawabe K, Sapru HN. Angiotensin-(1-12) in the rostral ventrolateral medullary pressor area of the rat elicits sympathoexcitatory responses. Exp Physiol 98: 94-108, 2013.
8. Arakawa K, Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 36: 638-641, 2000.
9. Arnold AC, Isa K, Shaltout HA, Nautiyal M, Ferrario CM, Chappell MC, Diz DI. Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. Am J Physiol Heart Circ Physiol 299: H763-H771, 2010.
10. Bader M, Alenina N, Andrade-Navarro MA, Santos RA. MAS and its related G protein-coupled receptors, Mrgprs. Pharmacol Rev 66: 1080-1105, 2014.
11. Baker KM, Kumar R. Intracellular angiotensin II induces cell proliferation independent of AT1 receptor. Am J Physiol Cell Physiol 291: C995-C1001, 2006.
12. Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, Phung OJ, White CM. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 151: 861-871, 2009.
13. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell=Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol Heart Circ Physiol 273: H1769-H1774, 1997.
14. Becari C, Teixeira FR, Oliveira EB, Salgado MC. Angiotensinconverting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol 301: H565-H570, 2011.
15. Belova LA. Angiotensin II-generating enzymes. Biochemistry (Mosc) 65: 1337-1345, 2000.
16. Berg T, Wassdal I, Sletten K. Immunohistochemical localization of rat submandibular gland esterase B (homologous to the RSKG-7 kallikrein gene) in relation to other serine proteases of the kallikrein family. J Histochem Cytochem 40: 83-92, 1992.
17. Boucher R, Demassieux S, Garcia R, Gutkowska Y, Genest J. [The tonin-angiotensin II system]. Union Med Can 106: 502-507, 1977.
18. Brugts JJ, van VL, Akkerhuis M, Bertrand M, Fox K, Mourad JJ, Boersma E. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-neededto- treat analysis. Int J Cardiol 181: 425-429, 2015.
19. Bujak-Gizycka B, Olszanecki R, Suski M, Madek J, Stachowicz A, Korbut R. Angiotensinogen metabolism in rat aorta: robust formation of proangiotensin-12. J Physiol Pharmacol 61: 679-682, 2010.
20. Burbach JP. Action of proteolytic enzymes on lipotropins and endorphins: biosynthesis, biotransformation and fate. Pharmacol Ther 24: 321-354, 1984.
21. Carey RM. Functional intracellular renin-angiotensin systems: potential for pathophysiology of disease. Am J Physiol Regul Integr Comp Physiol 302: R479-R481, 2012.
22. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 217: 141-154, 2007.
23. Cemassieux S, Boucher R, Crise C, Genest J. Purification and characterization of tonin. Can J Biochem 54: 788-795, 1976.
24. Chan KH, Chen YH, Zhang Y, Wong YH, Dun NJ. Angiotensin-[1-12] interacts with angiotensin type I receptors. Neuropharmacology 81: 267-273, 2014.
25. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science 271: 502-505, 1996.
26. Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol 310: H137-H152, 2016.
27. Chen LY, Li P, He Q, Jiang LQ, Cui CJ, Xu L, Liu LS. Transgenic study of the function of chymase in heart remodeling. J Hypertens 20: 2047-2055, 2002.
28. Chitravanshi VC, Proddutur A, Sapru HN. Cardiovascular actions of angiotensin-(1-12) in the hypothalamic paraventricular nucleus of the rat are mediated via angiotensin II. Exp Physiol 97: 1001-1017, 2012.
29. Chitravanshi VC, Sapru HN. Cardiovascular responses elicited by a new endogenous angiotensin in the nucleus tractus solitarius of the rat. Am J Physiol Heart Circ Physiol 300: H230-H240, 2011.
30. Cook JL, Re RN. Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model. Am J Physiol Regul Integr Comp Physiol 302: R482-R493, 2012.
31. Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res 89: 1138-1146, 2001.
32. Danser AH, van Kats JP, Admiraal PJ, Derkx FH, Lamers JM, Verdouw PD, Saxena PR, Schalekamp MA. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 24: 37-48, 1994.
33. De Mello WC. Influence of intracellular renin on heart cell communication. Hypertension 25: 1172-1177, 1995.
34. De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. Hypertension 32: 976-982, 1998.
35. De Mello WC. Angiotensin (1-7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. J Renin Angiotensin Aldosterone Syst 5: 203-208, 2004.
36. De Mello WC. Intracellular angiotensin II as a regulator of muscle tone in vascular resistance vessels. Pathophysiological implications. Peptides 78: 87-90, 2016.
37. De Mello WC, Danser AH. Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension 35: 1183-1188, 2000.
38. De Mello WC, Frohlich ED. On the local cardiac renin angiotensin system. Basic and clinical implications. Peptides 32: 1774-1779, 2011.
39. Dell’Italia LJ, Husain A. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol 17: 374-379, 2002.
40. Dell’Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, Durand J, Hankes GH, Oparil S. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 100: 253-258, 1997.
41. Dostal DE. The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. Regul Pept 91: 1-11, 2000.
42. Dzau VJ, Brenner A, Emmett N, Haber E. Identification of renin and renin-like enzymes in rat brain by a renin-specific antibody. Clin Sci (Lond) 59, Suppl 6: 45s-47s, 1980.
43. Ellis B, Li XC, Miguel-Qin E, Gu V, Zhuo JL. Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney. Am J Physiol Regul Integr Comp Physiol 302: R494-R509, 2012.
44. Feng Y. ANG II-independent prorenin/(pro)renin receptor signaling pathways in the central nervous system. Am J Physiol Heart Circ Physiol 309: H731-H733, 2015.
45. Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, Dell’Italia LJ. An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci (Lond) 126: 461-469, 2014.
46. Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted A, Tallant EA. Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension 18: III126-III133, 1991.
47. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin- converting enzyme 2. Circulation 111: 2605-2610, 2005.
48. Ferrario CM, Varagic J, Habibi J, Nagata S, Kato J, Chappell MC, Trask AJ, Kitamura K, Whaley-Connell A, Sowers JR. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol 296: H1184-H1192, 2009.
49. Ferrario CM, VonCannon J, Jiao Y, Ahmad S, Bader M, Dell’Italia LJ, Groban L, Varagic J. Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene. Am J Physiol Heart Circ Physiol 310: H995-H1002, 2016.
50. Forteza R, Lauredo I, Abraham WM, Conner GE. Bronchial tissue kallikrein activity is regulated by hyaluronic acid binding. Am J Respir Cell Mol Biol 21: 666-674, 1999.
51. Fu L, Wei CC, Powell PC, Bradley WE, Ahmad S, Ferrario CM, Collawn JF, Dell’Italia LJ. Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload. J Mol Cell Cardiol 92: 1-9, 2016.
52. Fu L, Wei CC, Powell PC, Bradley WE, Collawn JF, Dell’Italia LJ. Volume overload induces autophagic degradation of procollagen in cardiac fibroblasts. J Mol Cell Cardiol 89: 241-250, 2015.
53. Fukusen N, Kato Y, Kido H, Katunuma N. Kinetic studies on the inhibitions of mast cell chymase by natural serine protease inhibitors: indications for potential biological functions of these inhibitors. Biochem Med Metab Biol 38: 165-169, 1987.
54. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U, Ganten U. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S A 89: 7806-7810, 1992.
55. Gheorghiade M, Larson CJ, Shah SJ, Greene SJ, Cleland JGF, Colucci WS, Dunnmon P, Epstein SE, Kim RJ, Parsey RV, Stockbridge N, Carr J, Dinh W, Krahn T, Kramer F, Wahlander K, Deckelbaum LI, Crandall D, Okada S, Senni M, Sikora S, Sabbah HN, Butler J. Developing new treatments for heart failure. Focus on the heart. Circ Heart Fail 9: e002727, 2016.
56. Gutkowska J, Boucher R, Demassieux S, Garcia R, Genest J. A direct radioimmunoassay for tonin. Can J Biochem 56: 769-773, 1978.
57. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol 302: R518-R530, 2012.
58. Haas E, Lewis L, Koshy TJ, Varde AU, Renerts L, Bagai RC. Angiotensin II-producing enzyme III from acidified serum of nephrectomized dogs. Am J Hypertens 2: 696-707, 1989.
59. Hanssens M, Pijnenborg R, Keirse MJ, Vercruysse L, Verbist L, Van Assche FA. Renin-like immunoreactivity in uterus and placenta from normotensive and hypertensive pregnancies. Eur J Obstet Gynecol Reprod Biol 81: 177-184, 1998.
60. Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev 4: CD003040, 2012.
61. Hoshino F, Urata H, Inoue Y, Saito Y, Yahiro E, Ideishi M, Arakawa K, Saku K. Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 41, Suppl 1: S11-S18, 2003.
62. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14: 1738-1747, 2003.
63. Huber MJ, Basu R, Cecchettini C, Cuadra AE, Chen QH, Shan Z. Activation of the (pro)renin receptor in the paraventricular nucleus increases sympathetic outflow in anesthetized rats. Am J Physiol Heart Circ Physiol 309: H880-H887, 2015.
64. Husain A. The chymase-angiotensin system in humans. J Hypertens 11: 1155-1159, 1993.
65. Husain A, Smeby RR, Wilk D, Dzau VJ, Bumpus FM. Biochemical and immunological properties of dog brain isorenin. Endocrinology 114: 2210-2215, 1984.
66. Husain A, Wilk D, Smeby RR, Dzau VJ, Bumpus FM. Isorenin in dog brain and other tissues. Clin Exp Hypertens A 6: 1795-1799, 1984.
67. Isa K, Garcia-Espinosa MA, Arnold AC, Pirro NT, Tommasi EN, Ganten D, Chappell MC, Ferrario CM, Diz DI. Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol 297: R111-R115, 2009.
68. Jahanyar J, Youker KA, Loebe M, Assad-Kottner C, Koerner MM, Torre-Amione G, Noon GP. Mast cell-derived cathepsin g: a possible role in the adverse remodeling of the failing human heart. J Surg Res 140: 199-203, 2007.
69. Jankowski V, Toelle M, van der Giet M, Jankowski J. Angiotensin A, an ANG-II like peptide stimulating the AT2 receptor: PP.24461. J Hypertens 28: e1-e651, 2010.
70. Jessup JA, Trask AJ, Chappell MC, Nagata S, Kato J, Kitamura K, Ferrario CM. Localization of the novel angiotensin peptide, Angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol 294: H2614-H2618, 2008.
71. Kawabe T, Kawabe K, Sapru HN. Cardiovascular effect of angiotensin-(1-12) in the caudal ventrolateral medullary depressor area of the rat. Am J Physiol Heart Circ Physiol 306: H438-H449, 2014.
72. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, Abassi Z. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97: 946-953, 2005.
73. Khullar M, Scicli G, Carretero OA, Scicli AG. Purification and characterization of a serine protease (esterase B) from rat submandibular glands. Biochemistry 25: 1851-1857, 1986.
74. Kido H, Yokogoshi Y, Katunuma N. Kunitz-type protease inhibitor found in rat mast cells. Purification, properties, and amino acid sequence. J Biol Chem 263: 18104-18107, 1988.
75. Kjeldsen SE, Westheim AS, Os I. Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: LIFE, SCOPE, and VALUE. Curr Hypertens Rep 7: 155-157, 2005.
76. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 113: 1353-1360, 2006.
77. Komatsu Y, Kida N, Nozaki N, Kuwasako K, Nagata S, Kitamura K, Kato J. Effects of proangiotensin-12 infused continuously over 14 days in conscious rats. Eur J Pharmacol 683: 186-189, 2012.
78. Kumar R, Boim MA. Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens 18: 33-39, 2009.
79. Kumar R, Thomas CM, Yong QC, Chen W, Baker KM. The intracrine renin-angiotensin system. Clin Sci (Lond) 123: 273-284, 2012.
80. Kumar R, Yong QC, Thomas CM, Baker KM. Intracardiac intracellular angiotensin system in diabetes. Am J Physiol Regul Integr Comp Physiol 302: R510-R517, 2012.
81. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, Soares E, Barbosa C, Kjeldsen F, Oliveira A, Braga J, Savergnini S, Maia G, Peluso AB, Passos-Silva D, Ferreira A, Alves F, Martins A, Raizada M, Paula R, Motta-Santos D, Klempin F, Pimenta A, Alenina N, Sinisterra R, Bader M, Campagnole-Santos MJ, Santos RA. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112: 1104-1111, 2013.
82. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol 23: 238-243, 2003.
83. Li J, Jubair S, Levick SP, Janicki JS. The autocrine role of tryptase in pressure overload-induced mast cell activation, chymase release and cardiac fibrosis. IJC Metab Endocr 10: 16-23, 2016.
84. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, Dell’Italia LJ, Feneley MP, Graham RM, Husain A. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest 114: 112-120, 2004.
85. Lindpaintner K, Jin MW, Niedermaier N, Wilhelm MJ, Ganten D. Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res 67: 564-573, 1990.
86. Longley BJ, Tyrrell L, Ma Y, Williams DA, Halaban R, Langley K, Lu HS, Schechter NM. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci U S A 94: 9017-9021, 1997.
87. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107: 2555-2558, 2003.
88. McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 374: 1521-1532, 2016.
89. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993-1004, 2014.
90. Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, Tanaka H, Shindo M, Arakawa K. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 12: 1177-1181, 1994.
91. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 174: 821-825, 1991.
92. Moniwa N, Varagic J, Simington SW, Ahmad S, Nagata S, VonCannon JL, Ferrario CM. Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism. Am J Physiol Heart Circ Physiol 305: H644-H650, 2013.
93. Morgan L, Broughton PF, Kalsheker N. Angiotensinogen: molecular biology, biochemistry and physiology. Int J Biochem Cell Biol 28: 1211-1222, 1996.
94. Morris BJ. Human renin protein and gene structures: present and future targets for renin blockade in treatment of hypertension. J Hypertens Suppl 7: S9-S14, 1989.
95. Nagata S, Hatakeyama K, Asami M, Tokashiki M, Hibino H, Nishiuchi Y, Kuwasako K, Kato J, Asada Y, Kitamura K. Big angiotensin- 25: a novel glycosylated angiotensin-related peptide isolated from human urine. Biochem Biophys Res Commun 441: 757-762, 2013.
96. Nagata S, Kato J, Kuwasako K, Asami M, Kitamura K. Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system. Hypertens Res 35: 234-238, 2012.
97. Nagata S, Kato J, Kuwasako K, Kitamura K. Plasma and tissue levels of proangiotensin-12 and components of the renin-angiotensin system (RAS) following low- or high-salt feeding in rats. Peptides 31: 889-892, 2010.
98. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 350: 1026-1031, 2006.
99. Nagata S, Varagic J, Kon ND, Wang H, Groban L, Simington SW, Ahmad S, Dell’Italia LJ, VonCannon JL, Deal D, Ferrario CM. Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue. Ther Adv Cardiovasc Dis 9: 168-180, 2015.
100. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.
101. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/ reperfusion. J Pharmacol Exp Ther 339: 143-151, 2011.
102. Pat B, Killingsworth C, Chen Y, Gladden JD, Walcott G, Powell PC, Denney T, Gupta H, Desai R, Tillson M, Dillon AR, Dell’Italia LJ. Mast cell stabilization decreases cardiomyocyte and LV function in dogs with isolated mitral regurgitation. J Card Fail 16: 769-776, 2010.
103. Paul M, Poyan MA, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803, 2006.
104. Pejler G, Ronnberg E, Waern I, Wernersson S. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115: 4981-4990, 2010.
105. Peng H, Li W, Seth DM, Nair AR, Francis J, Feng Y. (Pro)renin receptor mediates both angiotensin II-dependent and -independent oxidative stress in neuronal cells. PLoS One 8: e58339, 2013.
106. Pereira HJ, Souza LL, Costa-Neto CM, Salgado MC, Oliveira EB. Carboxypeptidases A1 and A2 from the perfusate of rat mesenteric arterial bed differentially process angiotensin peptides. Peptides 33: 67-76, 2012.
107. Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, Costa Dias FL, Barcelos LS, Collares GB, Simoes E Silva AC. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol 46: 674-681, 2007.
108. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res 82: 40-50, 2009.
109. Prosser HC, Richards AM, Forster ME, Pemberton CJ. Regional vascular response to ProAngiotensin-12 (PA12) through the rat arterial system. Peptides 31: 1540-1545, 2010.
110. Puzyrev AA, Ivanova VF. [“Mixed” endocrine gland cells of the duodenal epithelium in various vertebrate animals and man]. Arkh Anat Gistol Embriol 90: 48-54, 1986.
111. Ramaha A, Patston PA. Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. Arch Biochem Biophys 397: 77-83, 2002.
112. Re RN. The cellular biology of angiotensin: paracrine, autocrine and intracrine actions in cardiovascular tissues. J Mol Cell Cardiol 21, Suppl 5: 63-69, 1989.
113. Re RN. A mechanism for mineralocortcoid participation in renal disease and heart failure. J Am Soc Hypertens 9: 586-591, 2015.
114. Rykl J, Thiemann J, Kurzawski S, Pohl T, Gobom J, Zidek W, Schluter H. Renal cathepsin G and angiotensin II generation. J Hypertens 24: 1797-1807, 2006.
115. Saris JJ, ‘t Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, Jan Danser AH. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 48: 564-571, 2006.
116. Satou R, Kobori H. Regulation of a novel angiotensin II precursor, proangiotensin-12, in the tissues by blockade of the renin-angiotensin system. Hypertens Res 35: 153-154, 2012.
117. Schiffrin EL, Garcia R, Gutkowska J, Boucher R, Genest J. Pressor effect of tonin in anephric animals. Can J Physiol Pharmacol 59: 864-871, 1981.
118. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucoseinduced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 293: H939-H948, 2007.
119. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 106: 439-453, 1957.
120. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 270: 4689-4696, 1995.
121. Takai S, Jin D, Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci 113: 301-309, 2010.
122. Takai S, Jin D, Miyazaki M. Multiple mechanisms for the action of chymase inhibitors. J Pharmacol Sci 118: 311-316, 2012.
123. Takai S, Jin D, Muramatsu M, Okamoto Y, Miyazaki M. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur J Pharmacol 501: 1-8, 2004.
124. Tani K, Ogushi F, Kido H, Kawano T, Kunori Y, Kamimura T, Cui P, Sone S. Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol 67: 585-589, 2000.
125. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280: 9291-9296, 2005.
126. Tewksbury DA. Quantitation of five forms of high molecular weight angiotensinogen from human placenta. Am J Hypertens 9: 1029-1034, 1996.
127. Tewksbury DA, Dart RA. High molecular weight angiotensinogen levels in hypertensive pregnant women. Hypertension 4: 729-734, 1982.
128. Tewksbury DA, Tryon ES. Immunochemical comparison of high molecular weight angiotensinogen from amniotic fluid, plasma of men, and plasma of pregnant women. Am J Hypertens 2: 411-413, 1989.
129. Tewksbury DA, Tryon ES, Burrill RE, Dart RA. High molecular weight angiotensinogen: a pregnancy associated protein. Clin Chim Acta 158: 7-12, 1986.
130. Tojo H, Urata H. Chymase inhibition and cardiovascular protection. Cardiovasc Drugs Ther 27: 139-143, 2013.
131. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 294: H2242-H2247, 2008.
132. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336: 1121-1123, 2008.
133. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25: 951-958, 2007.
134. Uehara Y, Miura S, Yahiro E, Saku K. Non-ACE pathway-induced angiotensin II production. Curr Pharm Des 19: 3054-3059, 2013.
135. Uehara Y, Urata H, Sasaguri M, Ideishi M, Sakata N, Tashiro T, Kimura M, Arakawa K. Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension 35: 55-60, 2000.
136. Urata H. Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease. J Renin Angiotensin Aldosterone Syst 1: S35-S37, 2000.
137. Urata H. [Involvement of chymase in pathogenesis of cardiovascular diseases]. Nihon Rinsho 62, Suppl 3: 147-151, 2004.
138. Urata H. [Chymase-dependent angiotensin II-formation]. Nihon Rinsho 63, Suppl 3: 60-64, 2005.
139. Urata H. Chymase and matrix metalloproteinase. Hypertens Res 30: 3-4, 2007.
140. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 91: 1269-1281, 1993.
141. Urata H, Ganten D. Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase. Eur Heart J 14, Suppl I: 177-182, 1993.
142. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66: 883-890, 1990.
143. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265: 22348-22357, 1990.
144. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens Suppl 12: S17-S22, 1994.
145. van der Leeuw J, Oemrawsingh RM, van der Graaf Y, Brugts JJ, Deckers JW, Bertrand M, Fox K, Ferrari R, Remme WJ, Simoons ML, Boersma E, Visseren FL. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA. Int J Cardiol 182: 194-199, 2015.
146. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158, 998 patients. Eur Heart J 33: 2088-2097, 2012.
147. Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med 6, Suppl 1: 45-51, 2011.
148. Varagic J, Ahmad S, VonCannon JL, Moniwa N, Brosnihan KB, Wysocki J, Batlle D, Ferrario CM. Predominance of AT1 blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats. Am J Hypertens 26: 583-590, 2013.
149. Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. J Mol Med (Berl) 86: 663-671, 2008.
150. Wang H, Jessup JA, Zhao Z, Da SJ, Lin M, MacNamara LM, Ahmad S, Chappell MC, Ferrario CM, Groban L. Characterization of the cardiac renin angiotensin system in oophorectomized and estrogenreplete mRen2.Lewis rats. PLoS One 8: e76992, 2013.
151. Wang J, Sukhova GK, Liu J, Ozaki K, Lesner A, Libby P, Kovanen PT, Shi GP. Cathepsin G deficiency reduces periaortic calcium chloride injury-induced abdominal aortic aneurysms in mice. J Vasc Surg 62: 1615-1624, 2015.
152. Wang Y, Shiota N, Leskinen MJ, Lindstedt KA, Kovanen PT. Mast cell chymase inhibits smooth muscle cell growth and collagen expression in vitro: transforming growth factor-beta1-dependent and -independent effects. Arterioscler Thromb Vasc Biol 21: 1928-1933, 2001.
153. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell’Italia LJ, Husain A. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 120: 1229-1239, 2010.
154. Westwood BM, Chappell MC. Divergent pathways for the angiotensin- (1-12) metabolism in the rat circulation and kidney. Peptides 35: 190-195, 2012.
155. Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, Ferrario CM, Sowers JR. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 296: F1013-F1022, 2009.
156. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 80: 219-227, 1997.
157. Xiong W, Chen LM, Chao J. Purification and characterization of a kallikrein-like T-kininogenase. J Biol Chem 265: 2822-2827, 1990.
158. Zhao XY, Zhao LY, Zheng QS, Su JL, Guan H, Shang FJ, Niu XL, He YP, Lu XL. Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 310: 159-166, 2008.
159. Zhao Z, Wang H, Lin M, Groban L. GPR30 decreases cardiac chymase/angiotensin II by inhibiting local mast cell number. Biochem Biophys Res Commun 459: 131-136, 2015.
160. Zheng J, Wei CC, Hase N, Shi K, Killingsworth CR, Litovsky SH, Powell PC, Kobayashi T, Ferrario CM, Rab A, Aban I, Collawn JF, Dell’Italia LJ. Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog. PLoS One 9: e94732, 2014.